Registry for patients with Thrombotic Thrombocytopenic Purpura in Turkey

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study involves 21 hematology centers across Turkey and aims to recruit 960 patients diagnosed with Thrombotic Thrombocytopenic Purpura (TTP). Participants will be followed for at least one year, during which data on their treatment and health outcomes will be collected through electronic case report forms. The study includes all patients diagnosed with aTTP since January 1, 2015, regardless of their treatment history. The goal is to gather comprehensive data to better understand the disease and its management in the Turkish population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed as aTTP after 01.01.2015
* Patients with ADAMS13\<10%
* Thrombocytopenia (\<100.000)
* Coombs (-)
* Microangiopathic hemolytic amenia
* 18 years and older

Exclusion Criteria:

\- Patient who does not sign informed consent form

Where it's running

• Baskent Universtiy Faculty of Medicine
  Ankara, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: ilker kurkcu
• Email: ilker.kurkcu@sentez-cro.com
• Phone: +905326354515

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients with immune-mediated thrombotic thrombocytopenic purpura in Italy

  This study is tracking patients with immune-mediated thrombotic thrombocytopenic purpura in Italy to see how the disease affects them over time and what their treatment outcomes are.

  Recruiting Fondazione Luigi Villa · Milan, MI · NCT06376786

• Creating a database for patients with Thrombotic Thrombocytopenic Purpura

  This study is creating a detailed database of information about patients with Thrombotic Thrombocytopenic Purpura to help better understand the condition.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT05571774

• cTTP patients treated with recombinant ADAMTS13: what happened after the early access program

  This study looks at people with congenital TTP who received recombinant ADAMTS13 to see how treatment changes their health before and after use.

  Recruiting Takeda · Cologne, North Rhine-Westphalia and 7 other locations · NCT07429942

• Adzynma in people with congenital TTP: a look at safety and antibody risk

  This study checks whether people with congenital TTP who have already received Adzynma develop neutralizing antibodies against Adzynma within six months of starting treatment.

  Recruiting at 6 sites Takeda · Vienna and 6 other locations · NCT07353099

• Long-term outcomes for people with immune TTP in the French national TMA cohort

  This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07205861

• Understanding the immune response in Thrombotic Thrombocytopenic Purpura

  This study is trying to understand how certain immune cells behave in people with Thrombotic Thrombocytopenic Purpura to see if they can help predict relapses and improve treatment.

  Recruiting University Hospital, Rouen · Rouen · NCT06945861

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.